STAAR Surgical director granted 11,145 stock options

STAAR Surgical director Richard T. LeBuhn received a new stock option grant as part of his director compensation.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

STAAR Surgical director Richard T. LeBuhn received a new stock option grant as part of his director compensation. He was granted options covering 11,145 shares of common stock at an exercise price of $29.12 per share, with no cash paid for the grant.

These options will vest and become exercisable on the earlier of June 18, 2027 or the company’s next annual shareholder meeting after the grant date, subject to his continuous service. LeBuhn also holds previously granted options covering 7,524 shares at an exercise price of $18.46 per share that are currently exercisable and expire in 2036.

Insider Trade Summary

Grant/Award: 11,145 shares

Grant/Award 2 txns

Insider LeBuhn Richard T.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	OPTION TO PURCHASE COMMON STOCK	11,145	$0.00	$0.00
holding	OPTION TO PURCHASE COMMON STOCK	--	--	--

Holdings After Transaction: OPTION TO PURCHASE COMMON STOCK — 18,669 contracts for 7,524 underlying shares (Direct)

Footnotes (3)

F1. These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Richard T. LeBuhn's (the "Reporting Person") continuous service with the Issuer.
F2. These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.
F3. These options are currently exercisable.

Key Figures

New option grant size: 11,145 options New option exercise price: $29.12 per share New option expiration: June 18, 2036 +3 more

6 metrics

New option grant size 11,145 options Director grant on June 18, 2026

New option exercise price $29.12 per share Grant to Richard T. LeBuhn

New option expiration June 18, 2036 Option term for 11,145-share grant

Existing options underlying shares 7,524 shares Previously granted, currently exercisable

Existing options exercise price $18.46 per share Earlier grant exercisable to 2036

Existing options expiration March 5, 2036 Option to purchase common stock

Key Terms

Amended and Restated Omnibus Equity Incentive Plan, director compensation, vest and become exercisable, continuous service

4 terms

Amended and Restated Omnibus Equity Incentive Plan financial

"These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended."

director compensation financial

"These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended."

vest and become exercisable financial

"These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's next annual meeting of shareholders after the grant date."

continuous service financial

"subject, in each case, to Richard T. LeBuhn's continuous service with the Issuer."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did STAAR Surgical (STAA) director Richard T. LeBuhn receive in this filing?

Richard T. LeBuhn received a grant of stock options covering 11,145 shares of STAAR Surgical common stock. The grant is part of his director compensation and allows him to buy shares at a fixed exercise price of $29.12 per share once the options vest.

When do Richard T. LeBuhn’s newly granted STAAR Surgical (STAA) options vest?

The new options vest on the earlier of June 18, 2027 or the date of STAAR Surgical’s next annual shareholder meeting after the June 18, 2026 grant. Vesting requires LeBuhn’s continuous service as a director with the company until that vesting date.

What is the exercise price and expiration date of the new STAAR Surgical (STAA) options?

The new options have an exercise price of $29.12 per share and expire on June 18, 2036. This means LeBuhn may purchase STAAR Surgical common stock at $29.12 per share any time after vesting and before the options expire, subject to plan terms.

Does Richard T. LeBuhn already hold other STAAR Surgical (STAA) stock options?

Yes. He holds previously granted options covering 7,524 shares of STAAR Surgical common stock at an $18.46 exercise price. According to the disclosure, these earlier options are currently exercisable and are scheduled to expire in March 2036 if not exercised.

How were the new STAAR Surgical (STAA) options to Richard T. LeBuhn issued?

The options were granted on June 18, 2026 as director compensation under STAAR Surgical’s Amended and Restated Omnibus Equity Incentive Plan. The grant involves no purchase price at grant; value arises only if the share price exceeds the $29.12 exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 07:40 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeBuhn Richard T.

(Last)

(First)

(Middle)

C/O BROADWOOD CAPITAL, INC.

156 WEST 56TH STREET, 3RD FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
OPTION TO PURCHASE COMMON STOCK	$29.12	06/18/2026		A		11,145		⁽¹⁾	06/18/2036	COMMON STOCK	11,145	$0⁽²⁾	11,145	D
OPTION TO PURCHASE COMMON STOCK	$18.46							⁽³⁾	03/05/2036	COMMON STOCK	7,524		7,524	D

Explanation of Responses:

1. These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Richard T. LeBuhn's (the "Reporting Person") continuous service with the Issuer.

2. These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.

3. These options are currently exercisable.

	/s/ Richard T. LeBuhn	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR